Therapy-related leukemia has been described after chemotherapy, radiation and autologous hematopoietic SCT. The majority of such cases are therapy-related AML/myelodysplastic syndrome (t-AML/MDS) and the cytogenetic and molecular features of these cases are well defined. 1 On the other hand, therapyrelated ALL (t-ALL) has been described infrequently in the literature. The clinical and pathological characteristics as well as treatment outcomes of t-ALL remain poorly defined. Although mixed myeloid leukemia (MLL) gene rearrangement is the most recurrent cytogenetic abnormality associated with t-ALL in the literature, other chromosomal alterations have been described. [2] [3] [4] [5] [6] [7] Herein, we examined the pathologic features and treatment outcomes of a cohort of t-ALL patients who underwent allogeneic hematopoietic cell transplantation (HCT) at our institution in order to better characterize the cytogenetic profile of t-ALL, and to examine outcomes of t-ALL post allogeneic HCT. We reviewed a consecutive case series of adult ALL patients who underwent allogeneic HCT at City of Hope between 1998 and 2014. We excluded patients with prior malignancies who did not receive chemotherapy or/and radiation before ALL onset. Continuous variables were tested between the leukemia cytogenetic abnormality subgroups, namely MLL gene rearrangement-positive and Phpositive, and others (all cases excluding those with MLL gene rearrangement and Ph chromosome) using the Wilcoxon ranksum test. Categorical variables were tested using Fisher's exact test. Survival estimates were calculated from the date of transplantation, and tested using the log-rank test of Mantel and Haenszel for OS and leukemia-free survival (LFS). Cumulative incidence of relapse (CIR) with non-relapse-related mortality (NRM) as a competing risk was plotted and tested using prevalence methods developed by Gray.
Among 596 adults with ALL who underwent allogeneic HCT during the specified period, we identified 28 (4.7%) patients who had a history of chemotherapy and/or radiation before the diagnosis of ALL. The median age was 48 years (range 29-61), and 57% of patients were female. All cases had B-cell phenotype. The median initial WBC was 8.0 × 10 9 /L (range 1.2-323). The median interval from initial diagnosis of malignancy/disease to ALL diagnosis was 7.3 years (range 0.9-50.1).
The most common prior diagnosis was breast cancer (N = 9), and this was followed by multiple myeloma (N = 4), sarcoma (N = 4), thyroid cancer/disease (N = 4), lymphoma (N = 3), germ cell tumor (N = 2, including a case of combined germ cell and CLL), melanoma (N = 1) and colon cancer (N = 1). Twenty-nine percent (N = 8) had a prior combination of chemotherapy and radiation therapy, 32% (N = 9) had prior radiation alone and 39% (N = 11) had prior chemotherapy alone. Four patients (14%) had undergone autologous HCT prior to ALL diagnosis.
Interestingly, the most common cytogenetic abnormality in our cohort was t(9;22)(q34;q11) (Ph chromosome) in 39% (N = 11) followed by MLL gene rearrangement in 25% (N = 7). MLL gene rearrangement were t(4;11) (N = 5), t(6;11) (N = 1) and t (1;11) (N = 1). Other observed cytogenetics include three cases of normal karyotype and single case of each of the following: complex karyotype;
hypodiploidy; 14q32/IGH+; t(1;5); t(12;17); t(1;19); and t(2;7). Therefore, we compared the clinical and pathological features of the three main cytogenetic subgroups: Ph+ t-ALL vs MLL gene-rearranged t-ALL vs t-ALL with other cytogenetic abnormalities. The median age, initial WBC and the type of previous cytotoxic modality were similar among the three cytogenetic subgroups. However, the median interval from the diagnosis of previous malignancy to ALL diagnosis was significantly longer for Ph+ t-ALL and other cytogenetics subgroups compared with the MLL generearrangement subgroup (9.37 vs 7.96 vs 2.07 years; P = 0.0006, respectively; Table 1 ).
The majority of patients were in CR1 at the time of transplantation (71%). Conditioning regimen for HCT was full intensity in 16 patients (57%). Tacrolimus/sirolimus-based GVHD prophylaxis was used in 16 patients (57%). Unrelated donor was the source of graft in 15 patients (54%) and mobilized peripheral blood progenitor cells were used in 23 patients (82%). Disease status at transplant, time from diagnosis to HCT, source of graft, GVHD prophylaxis and conditioning intensity were not different among the cytogenetic subgroups.
The 4-year LFS, OS, CIR and NRM for the whole cohort were 47%, 51%, 28% and 25%, respectively. For the patients transplanted in CR1 (N = 20), the 4-year LFS, OS and CIR were 58%, 65% and 23%, respectively, and LFS (P = 0.008) and OS (P = 0.02) were significantly higher for patients transplanted in CR1 compared with those transplanted in non-CR1 (N = 8). Outcomes were not different among the three cytogenetic subgroups (Figure 1) . One patient experienced relapse of the initial malignancy (CLL) after allogeneic HCT for t-ALL.
Given the fact that t-ALL constitutes a distinct minority among therapy-related leukemias, our study describes a relatively large number of t-ALL treated uniformly with alloHCT. Furthermore, we describe the cytogenetic features of this rare ALL subset and confirm the existence of therapy-related Ph+ ALL as a distinct entity.
There are case reports as well as a small case series in the published literature describing the outcome of secondary ALL. [5] [6] [7] However, not all these cases have received prior cytotoxic therapy, and hence, it is difficult to establish a causal relationship between therapy of the prior malignancy and subsequent occurrence of ALL in all of these cases. In contrast, we restricted the definition of t-ALL to cases with prior exposure to chemotherapy or/and radiation.
The GIMEMA group identified 21 (2.3%) cases of secondary ALL among 901 adults with ALL recorded in the database, but only 11 patients had prior treatment with cytotoxic therapy before ALL diagnosis. The median latency to development of secondary ALL from prior malignancy diagnosis was 27 months. Normal karyotype was the most common reported cytogenetic characteristic, but Ph chromosome was seen in three cases. The median survival was only 5 months. 5 Shivakumar et al. 6 pooled 101 cases of secondary ALL reported in the literature between the years 1982 and 2005, including 12 cases with no prior cytotoxic therapy. MLL gene rearrangement (N = 37) was the most commonly reported cytogenetic abnormality, but Ph chromosome was observed in 11 cases. Among the patients who were offered therapy for ALL, the median OS among different age subgroups ranged between 6 and 7.5 months. Only 14 patients underwent alloHCT. Tang et al. 7 reviewed 44 adults with secondary ALL treated at the MD Anderson Cancer Center, including 30 patients (6.2%) who received previous cytotoxic therapy before the onset of ALL. Therapy-related ALL had a shorter latency interval from prior malignancy diagnosis compared with secondary ALL (36 vs 144 months; P = 0.002). Among cases with t-ALL, MLL gene rearrangement and Ph chromosome were most common recurrent cytogenetic abnormalities and occurred at the same frequency (25%). Patients with secondary ALL had inferior OS (12 vs 45 months; P = 0.001) and LFS (11 vs 33 months; P = 0.003) when compared with de novo ALL, but there was no difference in outcome among patients with secondary ALL who did or did not have prior cytotoxic therapy exposure before the ALL onset. Only four patients with secondary ALL underwent alloHCT in this series.
Surprisingly, in contrast to previous reports, 5, 6 Ph+ ALL was the most common underlying cytogenetic abnormality in our cohort of t-ALL. This could be a biased observation as Ph+ ALL is considered a high-risk feature in ALL, which may have resulted in early referral of these patients for allogeneic HCT. Moreover, with the use of tyrosine kinase inhibitor therapy, it is possible that more Ph+ ALL cases than cases with other cytogenetic abnormalities may have been able to achieve remission and undergo allogeneic HCT. Thus, our HCT cohort could be enriched with Ph+ ALL for these reasons. However, on the basis of our series and other available data, 7 Ph+ ALL appears to be at least as common as MLL gene rearrangement among t-ALL.
The median interval from previous cancer diagnosis to ALL was over 7 years, which is slightly longer than what was reported for t-AML/MDS (4.5-5.4 years). 8 Latency was different among the different genetic groups, and the MLL subgroup had the shortest latency similar to t-AML/MDS, 8, 9 whereas Ph+ t-ALL has the longest latency from cancer diagnosis to ALL development.
The prognostic implication of t-ALL remains poorly defined. Although previous reports indicated poor prognosis for secondary ALL, 6, 7 the heterogeneity of cases classified as t-ALL makes it difficult to arrive at a firm conclusion. Our cohort has the advantage that it includes consecutive cases treated uniformly at the same institution with allogeneic HCT. The OS and LFS for our t-ALL cohort were comparable to those with de novo adult ALL transplanted in CR1 in other studies 10, 11 as well as being similar to a cohort of adults with ALL (N = 359) transplanted at our institution during the same period of time, who had a 3-year OS, LFS and CIR of 54%, 47% and 27%, respectively (Aldoss et al. unpublished data). Thus, t-ALL can be cured by allogeneic HCT with outcomes seemingly similar to de novo ALL. In contrast, t-ALL appears to fare poorly in comparison to de novo ALL when the majority of cases are treated with chemotherapy alone. 7 Non-relapse mortality appears to be acceptable among t-ALL patients despite prior exposure to cytotoxic therapy. Abbreviations: CI = confidence interval; CIR = cumulative incidence of relapse; HCT = hematopoietic cell transplantation; LFS = leukemia-free survival; MLL = mixed myeloid leukemia; NMC = non-myeloablative conditioning; RIC = reduced-intensity conditioning; t-ALL = therapy-related ALL. 
